145 related articles for article (PubMed ID: 37164948)
1. Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma.
Karam JA; Msaouel P; Haymaker CL; Matin SF; Campbell MT; Zurita AJ; Shah AY; Wistuba II; Marmonti E; Duose DY; Parra ER; Soto LMS; Laberiano-Fernandez C; Lozano M; Abraham A; Hallin M; Chin CD; Olson P; Der-Torossian H; Yan X; Tannir NM; Wood CG
Nat Commun; 2023 May; 14(1):2684. PubMed ID: 37164948
[TBL] [Abstract][Full Text] [Related]
2. Phase II Study of Neoadjuvant Nivolumab in Patients with Locally Advanced Clear Cell Renal Cell Carcinoma Undergoing Nephrectomy.
Carlo MI; Attalla K; Mazaheri Y; Gupta S; Yildirim O; Murray SJ; Coskey DT; Kotecha R; Lee CH; Feldman DR; Russo P; Patil S; Motzer RJ; Coleman JA; Durack JC; Chen YB; Akin O; Ari Hakimi A; Voss MH
Eur Urol; 2022 Jun; 81(6):570-573. PubMed ID: 35183395
[TBL] [Abstract][Full Text] [Related]
3. A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy.
Msaouel P; Goswami S; Thall PF; Wang X; Yuan Y; Jonasch E; Gao J; Campbell MT; Shah AY; Corn PG; Tam AL; Ahrar K; Rao P; Sircar K; Cohen L; Basu S; Duan F; Jindal S; Zhang Y; Chen H; Yadav SS; Shazer R; Der-Torossian H; Allison JP; Sharma P; Tannir NM
Sci Transl Med; 2022 Apr; 14(641):eabm6420. PubMed ID: 35442707
[TBL] [Abstract][Full Text] [Related]
4. A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma.
Msaouel P; Sweis RF; Bupathi M; Heath E; Goodman OB; Hoimes CJ; Milowsky MI; Davis N; Kalebasty AR; Picus J; Shaffer D; Mao S; Adra N; Yorio J; Gandhi S; Grivas P; Siefker-Radtke A; Yang R; Latven L; Olson P; Chin CD; Der-Torossian H; Mortazavi A; Iyer G
Eur Urol Oncol; 2023 Dec; ():. PubMed ID: 38105142
[TBL] [Abstract][Full Text] [Related]
5. MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy.
He K; Berz D; Gadgeel SM; Iams WT; Bruno DS; Blakely CM; Spira AI; Patel MR; Waterhouse DM; Richards DA; Pham A; Jotte R; Hong DS; Garon EB; Traynor A; Olson P; Latven L; Yan X; Shazer R; Leal TA
J Thorac Oncol; 2023 Jul; 18(7):907-921. PubMed ID: 36842467
[TBL] [Abstract][Full Text] [Related]
6. First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial.
Albiges L; Tannir NM; Burotto M; McDermott D; Plimack ER; Barthélémy P; Porta C; Powles T; Donskov F; George S; Kollmannsberger CK; Gurney H; Grimm MO; Tomita Y; Castellano D; Rini BI; Choueiri TK; Leung D; Saggi SS; Lee CW; McHenry MB; Motzer RJ
Eur Urol; 2022 Mar; 81(3):266-271. PubMed ID: 34750035
[TBL] [Abstract][Full Text] [Related]
7. Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity study.
Oliva M; Chepeha D; Araujo DV; Diaz-Mejia JJ; Olson P; Prawira A; Spreafico A; Bratman SV; Shek T; de Almeida J; R Hansen A; Hope A; Goldstein D; Weinreb I; Smith S; Perez-Ordoñez B; Irish J; Torti D; Bruce JP; Wang BX; Fortuna A; Pugh TJ; Der-Torossian H; Shazer R; Attanasio N; Au Q; Tin A; Feeney J; Sethi H; Aleshin A; Chen I; Siu L
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599023
[TBL] [Abstract][Full Text] [Related]
8. Real-world efficacy and safety of nivolumab plus ipilimumab in untreated metastatic renal cell carcinoma, and the impact of previous nephrectomy on clinical outcome: Japanese multi-institutional retrospective study.
Kato T; Fujita K; Minami T; Nagahara A; Hyashi Y; Nakata W; Matsuzaki K; Nakano K; Hatano K; Kawashima A; Imamura R; Takada S; Nishimura K; Tsujihata M; Takao T; Nakai Y; Nakayama M; Nishimura K; Uemura M; Uemura H; Nonomura N
Int J Clin Oncol; 2022 Oct; 27(10):1596-1604. PubMed ID: 35831538
[TBL] [Abstract][Full Text] [Related]
9. A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma.
Voss MH; Azad AA; Hansen AR; Gray JE; Welsh SJ; Song X; Kuziora M; Meinecke L; Blando J; Achour I; Wang Y; Walcott FL; Oosting SF
Clin Cancer Res; 2022 Jul; 28(14):3032-3041. PubMed ID: 35507017
[TBL] [Abstract][Full Text] [Related]
10. Impact of Cytoreductive Nephrectomy Following Nivolumab Plus Ipilimumab Therapy for Patients With Advanced Renal Cell Carcinoma.
Shirotake S; Miyama YU; Baba Y; Tajima H; Okada Y; Nakazawa K; Usami Y; Yasuda M; Igarashi D; Kaneko GO; Kanao K; Oyama M; Nishimoto K
Anticancer Res; 2022 May; 42(5):2727-2735. PubMed ID: 35489743
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.
Motzer RJ; Rini BI; McDermott DF; Arén Frontera O; Hammers HJ; Carducci MA; Salman P; Escudier B; Beuselinck B; Amin A; Porta C; George S; Neiman V; Bracarda S; Tykodi SS; Barthélémy P; Leibowitz-Amit R; Plimack ER; Oosting SF; Redman B; Melichar B; Powles T; Nathan P; Oudard S; Pook D; Choueiri TK; Donskov F; Grimm MO; Gurney H; Heng DYC; Kollmannsberger CK; Harrison MR; Tomita Y; Duran I; Grünwald V; McHenry MB; Mekan S; Tannir NM;
Lancet Oncol; 2019 Oct; 20(10):1370-1385. PubMed ID: 31427204
[TBL] [Abstract][Full Text] [Related]
12. FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy.
Choueiri TK; Kluger H; George S; Tykodi SS; Kuzel TM; Perets R; Nair S; Procopio G; Carducci MA; Castonguay V; Folefac E; Lee CH; Hotte SJ; Miller WH; Saggi SS; Lee CW; Desilva H; Bhagavatheeswaran P; Motzer RJ; Escudier B
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36328377
[TBL] [Abstract][Full Text] [Related]
13. Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial.
Motzer RJ; Escudier B; McDermott DF; Arén Frontera O; Melichar B; Powles T; Donskov F; Plimack ER; Barthélémy P; Hammers HJ; George S; Grünwald V; Porta C; Neiman V; Ravaud A; Choueiri TK; Rini BI; Salman P; Kollmannsberger CK; Tykodi SS; Grimm MO; Gurney H; Leibowitz-Amit R; Geertsen PF; Amin A; Tomita Y; McHenry MB; Saggi SS; Tannir NM
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32661118
[TBL] [Abstract][Full Text] [Related]
14. Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma.
Karam JA; Devine CE; Urbauer DL; Lozano M; Maity T; Ahrar K; Tamboli P; Tannir NM; Wood CG
Eur Urol; 2014 Nov; 66(5):874-80. PubMed ID: 24560330
[TBL] [Abstract][Full Text] [Related]
15. Tumor response in primary kidney lesions and metastatic lesions in nivolumab plus ipilimumab therapy for advanced renal cell carcinoma without prior nephrectomy: Preliminary results of a multi-institutional study.
Ishihara H; Takagi T; Yoshida K; Hashimoto Y; Kondo T; Tanabe K
Int J Urol; 2021 Oct; 28(10):1075-1076. PubMed ID: 34218475
[No Abstract] [Full Text] [Related]
16. Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial.
Vano YA; Elaidi R; Bennamoun M; Chevreau C; Borchiellini D; Pannier D; Maillet D; Gross-Goupil M; Tournigand C; Laguerre B; Barthélémy P; Coquan E; Gravis G; Houede N; Cancel M; Huillard O; Beuzeboc P; Fournier L; Méjean A; Cathelineau X; Doumerc N; Paparel P; Bernhard JC; de la Taille A; Bensalah K; Tricard T; Waeckel T; Pignot G; Braychenko E; Caruso S; Sun CM; Verkarre V; Lacroix G; Moreira M; Meylan M; Bougouïn A; Phan L; Thibault-Carpentier C; Zucman-Rossi J; Fridman WH; Sautès-Fridman C; Oudard S
Lancet Oncol; 2022 May; 23(5):612-624. PubMed ID: 35390339
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, phase IIIb/IV CheckMate 920 trial.
George DJ; Spigel DR; Gordan LN; Kochuparambil ST; Molina AM; Yorio J; Rezazadeh Kalebasty A; McKean H; Tchekmedyian N; Tykodi SS; Zhang J; Askelson M; Johansen JL; Hutson TE
BMJ Open; 2022 Sep; 12(9):e058396. PubMed ID: 36104138
[TBL] [Abstract][Full Text] [Related]
18. PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma.
Buckley HL; Collinson FJ; Ainsworth G; Poad H; Flanagan L; Katona E; Howard HC; Murden G; Banks RE; Brown J; Velikova G; Waddell T; Fife K; Nathan PD; Larkin J; Powles T; Brown SR; Vasudev NS
BMC Cancer; 2019 Nov; 19(1):1102. PubMed ID: 31727024
[TBL] [Abstract][Full Text] [Related]
19. A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapy.
Choueiri TK; Atkins MB; Rose TL; Alter RS; Ju Y; Niland K; Wang Y; Arbeit R; Parasuraman S; Gan L; McDermott DF
Invest New Drugs; 2021 Aug; 39(4):1019-1027. PubMed ID: 33507454
[TBL] [Abstract][Full Text] [Related]
20. Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial.
Motzer RJ; Escudier B; George S; Hammers HJ; Srinivas S; Tykodi SS; Sosman JA; Plimack ER; Procopio G; McDermott DF; Castellano D; Choueiri TK; Donskov F; Gurney H; Oudard S; Richardet M; Peltola K; Alva AS; Carducci M; Wagstaff J; Chevreau C; Fukasawa S; Tomita Y; Gauler TC; Kollmannsberger CK; Schutz FA; Larkin J; Cella D; McHenry MB; Saggi SS; Tannir NM
Cancer; 2020 Sep; 126(18):4156-4167. PubMed ID: 32673417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
